ADVANCE Study Ralinepag (IP receptor agonist)

DRUG/DEVICE
Ralinepag, extended-release tablets, for oral use
ROUTE OF ADMINISTRATION
Oral
THERAPEUTIC PLATFORM
NCE / Novel Biologics
CLINICAL TRIAL
TERRITORY
Worldwide, subject to out-licenses granted in the People’s Republic of China and certain other Asian territories
STATUS
Phase 3
Ralinepag is a development-stage product not approved for sale in any jurisdiction.